tradingkey.logo
搜索

Uniqure NV

QURE
添加自选
43.630USD
+1.440+3.41%
收盘 07-31 16:00美东报价延迟15分钟
3.03B总市值
亏损市盈率 TTM

关于 Uniqure NV 公司

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Uniqure NV简介

公司代码QURE
公司名称Uniqure NV
上市日期Feb 05, 2014
CEOKapusta (Matthew)
员工数量209
证券类型Ordinary Share
年结日Feb 05
公司地址Paasheuvelweg 25a
城市AMSTERDAM
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Netherlands
邮编1105 BP
电话31202406000
网址https://www.uniqure.com/
公司代码QURE
上市日期Feb 05, 2014
CEOKapusta (Matthew)

Uniqure NV公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
42.30K
-50.67%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
27.52K
+20.19%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
25.93K
+21.43%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
42.30K
-50.67%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%

常见问题

Uniqure NV的前五大股东是谁?

Uniqure NV 的前五大股东如下:Mr. Christian Klemt, CPA

有多少机构持有Uniqure NV(QURE)的股份?

截至2026Q1,共有481家机构持有Uniqure NV的股份,合计持有的股份价值约为65.80M,占公司总股份的104.34%。与2025Q4相比,机构持股有所增加,增幅为1601871.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有